Human Leukocyte Antigen-G Polymorphisms Association With Cancer Post-Heart Transplantation

Julieta Lazarte, Livia Goldraich, Cedric Manlhiot, Stella Kozuszko, Vivek Rao, Diego Delgado

Research output: Contribution to journalArticle

Abstract

Background Post transplantation, a major complication is the development of malignancies. Human Leukocyte Antigen (HLA)-G is a molecule that inhibits the immune system and it is utilized by malignant cells to hide from the immune system. Expression of HLA-G from the donor and recipient cells in transplant patients is regulated by gene variations however, the association between genotype and cancer remains unknown. Our objective was to determine the association between genotype and outcome. Methods Heart transplant recipients (251) and available corresponding donors (196) samples were genotyped for polymorphisms and the association of polymorphisms to outcome was evaluated with parametric hazard regression models. Results Risk of cancer was 22% at 10 years post-transplantation. The mean follow-up was of 4.9 ± 3.6 years. In a multivariable analysis, donor–recipient SNP 3187 matching was identified as a protective factor for cancer (hazard ratio 0.43; 95% confidence interval 0.19–0.93; p = 0.03). While coding region allele (haplotype 6) was identified as an independent risk factor (hazard ratio 3.7; 95% confidence interval 1.36–10.06; p = 0.01). Conclusion In this investigation, we identified an association between cancer post-transplantation and HLA-G polymorphisms, which may reveal a pathway for potential diagnostic and therapeutic strategies for cancer post-transplantation.

Original languageEnglish (US)
Pages (from-to)805-811
Number of pages7
JournalHuman Immunology
Volume77
Issue number9
DOIs
StatePublished - Sep 1 2016
Externally publishedYes

Fingerprint

Heart Transplantation
HLA Antigens
Transplantation
Neoplasms
Immune System
Genotype
Tissue Donors
Confidence Intervals
Proportional Hazards Models
Haplotypes
Single Nucleotide Polymorphism
Alleles
Transplants
Genes

Keywords

  • Cancer
  • HLA-G
  • HLA-G polymorphisms
  • Post-heart transplantation

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Human Leukocyte Antigen-G Polymorphisms Association With Cancer Post-Heart Transplantation. / Lazarte, Julieta; Goldraich, Livia; Manlhiot, Cedric; Kozuszko, Stella; Rao, Vivek; Delgado, Diego.

In: Human Immunology, Vol. 77, No. 9, 01.09.2016, p. 805-811.

Research output: Contribution to journalArticle

Lazarte, Julieta ; Goldraich, Livia ; Manlhiot, Cedric ; Kozuszko, Stella ; Rao, Vivek ; Delgado, Diego. / Human Leukocyte Antigen-G Polymorphisms Association With Cancer Post-Heart Transplantation. In: Human Immunology. 2016 ; Vol. 77, No. 9. pp. 805-811.
@article{a9a0d539115d42d2919f13adde9ae955,
title = "Human Leukocyte Antigen-G Polymorphisms Association With Cancer Post-Heart Transplantation",
abstract = "Background Post transplantation, a major complication is the development of malignancies. Human Leukocyte Antigen (HLA)-G is a molecule that inhibits the immune system and it is utilized by malignant cells to hide from the immune system. Expression of HLA-G from the donor and recipient cells in transplant patients is regulated by gene variations however, the association between genotype and cancer remains unknown. Our objective was to determine the association between genotype and outcome. Methods Heart transplant recipients (251) and available corresponding donors (196) samples were genotyped for polymorphisms and the association of polymorphisms to outcome was evaluated with parametric hazard regression models. Results Risk of cancer was 22{\%} at 10 years post-transplantation. The mean follow-up was of 4.9 ± 3.6 years. In a multivariable analysis, donor–recipient SNP 3187 matching was identified as a protective factor for cancer (hazard ratio 0.43; 95{\%} confidence interval 0.19–0.93; p = 0.03). While coding region allele (haplotype 6) was identified as an independent risk factor (hazard ratio 3.7; 95{\%} confidence interval 1.36–10.06; p = 0.01). Conclusion In this investigation, we identified an association between cancer post-transplantation and HLA-G polymorphisms, which may reveal a pathway for potential diagnostic and therapeutic strategies for cancer post-transplantation.",
keywords = "Cancer, HLA-G, HLA-G polymorphisms, Post-heart transplantation",
author = "Julieta Lazarte and Livia Goldraich and Cedric Manlhiot and Stella Kozuszko and Vivek Rao and Diego Delgado",
year = "2016",
month = "9",
day = "1",
doi = "10.1016/j.humimm.2016.01.005",
language = "English (US)",
volume = "77",
pages = "805--811",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - Human Leukocyte Antigen-G Polymorphisms Association With Cancer Post-Heart Transplantation

AU - Lazarte, Julieta

AU - Goldraich, Livia

AU - Manlhiot, Cedric

AU - Kozuszko, Stella

AU - Rao, Vivek

AU - Delgado, Diego

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Background Post transplantation, a major complication is the development of malignancies. Human Leukocyte Antigen (HLA)-G is a molecule that inhibits the immune system and it is utilized by malignant cells to hide from the immune system. Expression of HLA-G from the donor and recipient cells in transplant patients is regulated by gene variations however, the association between genotype and cancer remains unknown. Our objective was to determine the association between genotype and outcome. Methods Heart transplant recipients (251) and available corresponding donors (196) samples were genotyped for polymorphisms and the association of polymorphisms to outcome was evaluated with parametric hazard regression models. Results Risk of cancer was 22% at 10 years post-transplantation. The mean follow-up was of 4.9 ± 3.6 years. In a multivariable analysis, donor–recipient SNP 3187 matching was identified as a protective factor for cancer (hazard ratio 0.43; 95% confidence interval 0.19–0.93; p = 0.03). While coding region allele (haplotype 6) was identified as an independent risk factor (hazard ratio 3.7; 95% confidence interval 1.36–10.06; p = 0.01). Conclusion In this investigation, we identified an association between cancer post-transplantation and HLA-G polymorphisms, which may reveal a pathway for potential diagnostic and therapeutic strategies for cancer post-transplantation.

AB - Background Post transplantation, a major complication is the development of malignancies. Human Leukocyte Antigen (HLA)-G is a molecule that inhibits the immune system and it is utilized by malignant cells to hide from the immune system. Expression of HLA-G from the donor and recipient cells in transplant patients is regulated by gene variations however, the association between genotype and cancer remains unknown. Our objective was to determine the association between genotype and outcome. Methods Heart transplant recipients (251) and available corresponding donors (196) samples were genotyped for polymorphisms and the association of polymorphisms to outcome was evaluated with parametric hazard regression models. Results Risk of cancer was 22% at 10 years post-transplantation. The mean follow-up was of 4.9 ± 3.6 years. In a multivariable analysis, donor–recipient SNP 3187 matching was identified as a protective factor for cancer (hazard ratio 0.43; 95% confidence interval 0.19–0.93; p = 0.03). While coding region allele (haplotype 6) was identified as an independent risk factor (hazard ratio 3.7; 95% confidence interval 1.36–10.06; p = 0.01). Conclusion In this investigation, we identified an association between cancer post-transplantation and HLA-G polymorphisms, which may reveal a pathway for potential diagnostic and therapeutic strategies for cancer post-transplantation.

KW - Cancer

KW - HLA-G

KW - HLA-G polymorphisms

KW - Post-heart transplantation

UR - http://www.scopus.com/inward/record.url?scp=84955298432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955298432&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2016.01.005

DO - 10.1016/j.humimm.2016.01.005

M3 - Article

C2 - 26776459

AN - SCOPUS:84955298432

VL - 77

SP - 805

EP - 811

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 9

ER -